INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $107.98 million. The enterprise value is $77.34 million.

Market Cap	107.98M
Enterprise Value	77.34M

Important Dates

The last earnings date was Thursday, October 31, 2024, after market close.

Earnings Date	Oct 31, 2024
Ex-Dividend Date	n/a

Share Statistics

INmune Bio has 22.17 million shares outstanding. The number of shares has increased by 5.16% in one year.

Current Share Class	22.17M
Shares Outstanding	22.17M
Shares Change (YoY)	+5.16%
Shares Change (QoQ)	+4.55%
Owned by Insiders (%)	20.40%
Owned by Institutions (%)	26.90%
Float	14.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.79
P/TBV Ratio	4.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,841.45
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.08.

Current Ratio	2.59
Quick Ratio	2.53
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-23.93

Financial Efficiency

Return on equity (ROE) is -98.97% and return on invested capital (ROIC) is -52.34%.

Return on Equity (ROE)	-98.97%
Return on Assets (ROA)	-44.97%
Return on Capital (ROIC)	-52.34%
Revenue Per Employee	$2,471
Profits Per Employee	-$2.43M
Employee Count	17
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.43% in the last 52 weeks. The beta is 1.85, so INmune Bio's price volatility has been higher than the market average.

Beta (5Y)	1.85
52-Week Price Change	-38.43%
50-Day Moving Average	5.38
200-Day Moving Average	8.52
Relative Strength Index (RSI)	39.31
Average Volume (20 Days)	239,319

Short Selling Information

The latest short interest is 3.48 million, so 15.71% of the outstanding shares have been sold short.

Short Interest	3.48M
Short Previous Month	2.83M
Short % of Shares Out	15.71%
Short % of Float	24.34%
Short Ratio (days to cover)	14.05

Income Statement

In the last 12 months, INmune Bio had revenue of $42,000 and -$41.27 million in losses. Loss per share was -$2.19.

Revenue	42,000
Gross Profit	42,000
Operating Income	-41.55M
Pretax Income	-37.74M
Net Income	-41.27M
EBITDA	n/a
EBIT	-41.55M
Loss Per Share	-$2.19

Full Income Statement

Balance Sheet

The company has $33.55 million in cash and $2.91 million in debt, giving a net cash position of $30.64 million or $1.38 per share.

Cash & Cash Equivalents	33.55M
Total Debt	2.91M
Net Cash	30.64M
Net Cash Per Share	$1.38
Equity (Book Value)	38.68M
Book Value Per Share	1.74
Working Capital	22.03M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-25.75M
Capital Expenditures	n/a
Free Cash Flow	-25.75M
FCF Per Share	-$1.16

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-98,921.43%
Pretax Margin	-98,266.67%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-27,090.59%

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.16%
Shareholder Yield	-5.16%
Earnings Yield	-38.22%
FCF Yield	-23.85%

Analyst Forecast

The average price target for INmune Bio is $21.00, which is 331.21% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$21.00
Price Target Difference	331.21%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	302.39%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

INmune Bio has an Altman Z-Score of 1.26 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.26
Piotroski F-Score	1